Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Deppert

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Oncogene|February 16, 1999
Surface plasmon resonance measurements reveal stable complex formation between p53 and DNA polymerase alphaC Kühn, F Müller, C Melle, et al.
International Journal of Oncology|December 24, 1998
TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expressionM Voss, B Wolff, N Savitskaia, et al.
Current Topics in Microbiology and Immunology|January 1, 1984
Properties of the myc-gene product: nuclear association, inhibition of transcription and activation in stimulated lymphocytesK Moelling, T Benter, T Bunte, et al.
Oncogene|December 5, 2000
IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effectsL Behrend, D M Milne, M Stöter, et al.
Molecular and Cellular Biology|March 22, 2001
Two immunologically distinct human DNA polymerase alpha-primase subpopulations are involved in cellular DNA replicationS Dehde, G Rohaly, O Schub, et al.
Cell Death and Differentiation|November 19, 2011
Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 WorkshopG Blandino, W Deppert, P Hainaut, et al.
International Journal of Oncology|May 14, 2011
Wild-type p53 is not involved in reversion of the tumorigenic phenotype of breast-cancer cells after transfer of normal chromosome-17M Theile, S Hartmann, H Naundorf, et al.
Cell Death and Differentiation|December 1, 2007
Notch1 activation reduces proliferation in the multipotent hematopoietic progenitor cell line FDCP-mix through a p53-dependent pathway but Notch1 effects on myeloid and erythroid differentiation are independent of p53K Henning, J Heering, R Schwanbeck, et al.
Oncogene|February 2, 1995
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genesM Theile, S Hartmann, H Scherthan, et al.
Anticancer Research|April 9, 2005
Comparative assessment of the functional p53 status in glioma cellsE L Kim, K Yoshizato, L Kluwe, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Oncogene|February 16, 1999
Surface plasmon resonance measurements reveal stable complex formation between p53 and DNA polymerase alphaC Kühn, F Müller, C Melle, et al.
International Journal of Oncology|December 24, 1998
TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expressionM Voss, B Wolff, N Savitskaia, et al.
Current Topics in Microbiology and Immunology|January 1, 1984
Properties of the myc-gene product: nuclear association, inhibition of transcription and activation in stimulated lymphocytesK Moelling, T Benter, T Bunte, et al.
Oncogene|December 5, 2000
IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effectsL Behrend, D M Milne, M Stöter, et al.
Molecular and Cellular Biology|March 22, 2001
Two immunologically distinct human DNA polymerase alpha-primase subpopulations are involved in cellular DNA replicationS Dehde, G Rohaly, O Schub, et al.
Cell Death and Differentiation|November 19, 2011
Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 WorkshopG Blandino, W Deppert, P Hainaut, et al.
International Journal of Oncology|May 14, 2011
Wild-type p53 is not involved in reversion of the tumorigenic phenotype of breast-cancer cells after transfer of normal chromosome-17M Theile, S Hartmann, H Naundorf, et al.
Cell Death and Differentiation|December 1, 2007
Notch1 activation reduces proliferation in the multipotent hematopoietic progenitor cell line FDCP-mix through a p53-dependent pathway but Notch1 effects on myeloid and erythroid differentiation are independent of p53K Henning, J Heering, R Schwanbeck, et al.
Oncogene|February 2, 1995
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genesM Theile, S Hartmann, H Scherthan, et al.
Anticancer Research|April 9, 2005
Comparative assessment of the functional p53 status in glioma cellsE L Kim, K Yoshizato, L Kluwe, et al.
Pageof 15